Announcement on Preliminary Earnings Estimate for 2025
Filed with SSE · · 3 pages · Chinese
Liaoning Chengda Biotechnology Co. Ltd. on 6ix
Earlier from Liaoning Chengda Biotechnology
- Announcement on Obtaining the Drug Registration Certificate for Freeze-dried Rabies Vaccine (Human Diploid Cell)
- Announcement on Obtaining Notice of Approval for Drug Clinical Trials for Influenza Virus Split Vaccine (High Dose)
- Announcement on Outward Investing in Establishing a Wholly-owned Subsidiary
- Announcement on Subsidiary Opening a Special Account for Raised Funds and Signing a Tripartite Supervision Agreement on Special Account Deposit of Raised Funds
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
Later from Liaoning Chengda Biotechnology
- Announcement on Wholly-owned Subsidiary's Passing GMP Compliance Inspection for Drugs
- Announcement on the Resignation of Independent Directors upon Expiration of Their Term
- Announcement on Obtaining the Approval for Supplementary Application for Drugs for the Core Product Freeze-dried Rabies Vaccine (Vero Cells)
- Announcement on 2025 Annual Profit Distribution Plan
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
Follow Liaoning Chengda Biotechnology into a list and get an email when it puts out news.
Follow Liaoning Chengda Biotechnology